Get access

Sorafenib in patients with refractory or recurrent multiple myeloma

Authors

  • Anna Yordanova,

    1. Department of Internal Medicine III, Center for Integrated Oncology (CIO), University of Bonn, Bonn, Germany
    Search for more papers by this author
    • Anna Yordanova, Dirk Hose, Hartmut Goldschmidt and Ingo G. H. Schmidt-Wolf are the authors that contributed equally to the work. For the German Refractory Myeloma Study Group.
  • Dirk Hose,

    1. Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
    Search for more papers by this author
    • Anna Yordanova, Dirk Hose, Hartmut Goldschmidt and Ingo G. H. Schmidt-Wolf are the authors that contributed equally to the work. For the German Refractory Myeloma Study Group.
  • Kai Neben,

    1. Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
    Search for more papers by this author
  • Mathias Witzens-Harig,

    1. Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
    Search for more papers by this author
  • Ines Gütgemann,

    1. Institute of Pathology, University of Bonn, Bonn, Germany
    Search for more papers by this author
  • Marc-Steffen Raab,

    1. Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
    Search for more papers by this author
  • Thomas Moehler,

    1. Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
    Search for more papers by this author
  • Hartmut Goldschmidt,

    1. Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
    Search for more papers by this author
    • Anna Yordanova, Dirk Hose, Hartmut Goldschmidt and Ingo G. H. Schmidt-Wolf are the authors that contributed equally to the work. For the German Refractory Myeloma Study Group.
  • Ingo GH Schmidt-Wolf

    Corresponding author
    1. Department of Internal Medicine III, Center for Integrated Oncology (CIO), University of Bonn, Bonn, Germany
    • Correspondence to: Ingo G. H. Schmidt-Wolf, Department of Internal Medicine III, Center for Integrated Oncology (CIO), University Hospital Bonn, Sigmund-Freud-Str. 25, 53105 Bonn, Germany.

      E-mail: Ingo.Schmidt-Wolf@ukb.uni-bonn.de

    Search for more papers by this author
    • Anna Yordanova, Dirk Hose, Hartmut Goldschmidt and Ingo G. H. Schmidt-Wolf are the authors that contributed equally to the work. For the German Refractory Myeloma Study Group.

Abstract

Sorafenib is a small molecular inhibitor of several tyrosine protein kinases, including vascular endothelial growth factor receptor, platelet-derived growth factor receptor and rapidly accelerated fibrosarcoma kinases, targeting signal transduction and angiogenic pathways. It is approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma. The objectives of this prospective phase II trial were to assess the activity and tolerability of sorafenib in patients with recurrent or refractory myeloma. In total, 11 patients were enrolled. Patients received 2 × 200 mg of sorafenib orally twice daily until completing 13 full cycles or disease progression. Of the side effects, 8.8% grade 3 and 1.1% grade 4 occurred. Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24.4 months and 6.9 month, respectively. Further clinical investigations are recommended to investigate sorafenib single agent activity in myeloma subgroups with ras-/BRAF-/vascular endothelial growth factor receptor pathway activation and combination therapy approaches. Copyright © 2013 John Wiley & Sons, Ltd.

Ancillary